MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from exercise of
warrants
$5,388K
Proceeds from employee
options exercised
$227K
Net cash provided by
financing activities
$5,561K
Canceled cashflow
$54K
Net (decrease)
increase in cash, cash...
-$4,848K
Canceled cashflow
$5,561K
Stock-based compensation
$1,172K
Prepaid expenses and
other current assets
-$434K
Depreciation and
amortization expense
$188K
Accounts receivable
-$154K
Net income (loss)
attributable to...
$23K
Loss on disposal of
assets
-$12K
Maturities of marketable
debt securities
$5,965K
Common shares received
and retired for...
$40K
Payment of finance lease
liabilities
$14K
Net cash used in
operating activities
-$8,078K
Canceled cashflow
$1,983K
Net cash (used in)
provided by investing...
-$2,326K
Effect of exchange rate
changes on cash, cash...
-$5K
Canceled cashflow
$5,965K
Net loss
attributable to lineage
-$4,812K
Change in fair value of
warrant liability
-$2,324K
Accounts payable and
accrued liabilities
-$1,711K
Deferred revenue
-$995K
Accretion of income on
marketable debt securities
$163K
Foreign currency
remeasurement
$24K
(gain) loss on
marketable equity...
$24K
Change in right-of-use
assets and liabilities
-$8K
Purchases of marketable
debt securities
$8,236K
Purchase of equipment
$55K
Back
Back
Cash Flow
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX)
source: myfinsight.com